Discovery - University of Dundee - Online Publications

Library & Learning Centre

Antifungal therapy in European hospitals

Standard

Antifungal therapy in European hospitals : data from the ESAC point-prevalence surveys 2008 and 2009. / ESAC-3 Hosp Care Subproject Grp.

In: Clinical Microbiology and Infection, Vol. 18, No. 10, 10.2012, p. E389-E395.

Research output: Contribution to journalArticle

Harvard

ESAC-3 Hosp Care Subproject Grp 2012, 'Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009' Clinical Microbiology and Infection, vol 18, no. 10, pp. E389-E395., 10.1111/j.1469-0691.2012.03973.x

APA

ESAC-3 Hosp Care Subproject Grp (2012). Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009. Clinical Microbiology and Infection, 18(10), E389-E395. 10.1111/j.1469-0691.2012.03973.x

Vancouver

ESAC-3 Hosp Care Subproject Grp. Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009. Clinical Microbiology and Infection. 2012 Oct;18(10):E389-E395. Available from: 10.1111/j.1469-0691.2012.03973.x

Author

ESAC-3 Hosp Care Subproject Grp / Antifungal therapy in European hospitals : data from the ESAC point-prevalence surveys 2008 and 2009.

In: Clinical Microbiology and Infection, Vol. 18, No. 10, 10.2012, p. E389-E395.

Research output: Contribution to journalArticle

Bibtex - Download

@article{a8e37504d0a8413a8a351f66c0680571,
title = "Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009",
author = "P. Zarb and B. Amadeo and A. Muller and N. Drapier and V. Vankerckhoven and P. Davey and H. Goossens",
year = "2012",
doi = "10.1111/j.1469-0691.2012.03973.x",
volume = "18",
number = "10",
pages = "E389--E395",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Antifungal therapy in European hospitals

T2 - data from the ESAC point-prevalence surveys 2008 and 2009

A1 - Zarb,P.

A1 - Amadeo,B.

A1 - Muller,A.

A1 - Drapier,N.

A1 - Vankerckhoven,V.

A1 - Davey,P.

A1 - Goossens,H.

AU - Zarb,P.

AU - Amadeo,B.

AU - Muller,A.

AU - Drapier,N.

AU - Vankerckhoven,V.

AU - Davey,P.

AU - Goossens,H.

PY - 2012/10

Y1 - 2012/10

N2 - Clin Microbiol Infect The study aimed to identify targets for quality improvement in antifungal use in European hospitals and determine the variability of such prescribing. Hospitals that participated in the European Surveillance of Antimicrobial Consumption Point Prevalence Surveys (ESAC-PPS) were included. The WHO Anatomical Therapeutic Chemical (ATC) classification for 'antimycotics for systemic use' (J02) 2009 version was used. Demographic data and information about indications and diagnoses were collected in 2008 and 2009. From 99053 patients, 29324 (29.6%) received antimicrobials. Antifungals represented 1529 of 40878 (3.7%) antimicrobials. Antifungals were mainly (54.2%) administered orally. Hospital-acquired infections represented 44.5% of indications for antifungals followed by medical prophylaxis at 31.2%. The site of infection was not defined in 36.0% of cases but the most commonly targeted sites were respiratory (19.2%) and gastrointestinal (18.8%). The most used antifungal was fluconazole (60.5%) followed by caspofungin (10.5%). Antifungal-antibacterial combinations were frequently used (77.5%). The predominance of fluconazole use in participating hospitals could result in an increase in prevalence of inherently resistant fungi, increasing the need for newer antifungals. Although acknowledging that antifungal prophylaxis in the immunocompromised host needs further exploration, repetitive surveys using ESAC-PPS methodology may help to monitor the effects of interventions set to regulate antifungal use. © 2012 European Society of Clinical Microbiology and Infectious Diseases.

AB - Clin Microbiol Infect The study aimed to identify targets for quality improvement in antifungal use in European hospitals and determine the variability of such prescribing. Hospitals that participated in the European Surveillance of Antimicrobial Consumption Point Prevalence Surveys (ESAC-PPS) were included. The WHO Anatomical Therapeutic Chemical (ATC) classification for 'antimycotics for systemic use' (J02) 2009 version was used. Demographic data and information about indications and diagnoses were collected in 2008 and 2009. From 99053 patients, 29324 (29.6%) received antimicrobials. Antifungals represented 1529 of 40878 (3.7%) antimicrobials. Antifungals were mainly (54.2%) administered orally. Hospital-acquired infections represented 44.5% of indications for antifungals followed by medical prophylaxis at 31.2%. The site of infection was not defined in 36.0% of cases but the most commonly targeted sites were respiratory (19.2%) and gastrointestinal (18.8%). The most used antifungal was fluconazole (60.5%) followed by caspofungin (10.5%). Antifungal-antibacterial combinations were frequently used (77.5%). The predominance of fluconazole use in participating hospitals could result in an increase in prevalence of inherently resistant fungi, increasing the need for newer antifungals. Although acknowledging that antifungal prophylaxis in the immunocompromised host needs further exploration, repetitive surveys using ESAC-PPS methodology may help to monitor the effects of interventions set to regulate antifungal use. © 2012 European Society of Clinical Microbiology and Infectious Diseases.

UR - http://www.scopus.com/inward/record.url?scp=84864113230&partnerID=8YFLogxK

U2 - 10.1111/j.1469-0691.2012.03973.x

DO - 10.1111/j.1469-0691.2012.03973.x

M1 - Article

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 10

VL - 18

SP - E389-E395

ER -

Documents

Library & Learning Centre

Contact | Accessibility | Policy